In a retrospective study of a large number of luminal/HER2-negative breast cancer patients, the data demonstrated that a p53 expression of ≥50% (present in 9% patients) was associated with shorter disease-free survival, in comparison to patients with p53 expression of <50%. Here, TP53 is linked to breast cancer.